Wuhan Hvsen Financials
| 300871 Stock | 11.01 0.60 5.17% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 82.1 M | 41.9 M |
|
|
Wuhan | Select Account or Indicator |
Understanding current and past Wuhan Hvsen Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Wuhan Hvsen's financial statements are interrelated, with each one affecting the others. For example, an increase in Wuhan Hvsen's assets may result in an increase in income on the income statement.
Please note, the presentation of Wuhan Hvsen's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Wuhan Hvsen's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Wuhan Hvsen's management manipulating its earnings.
Wuhan Hvsen Stock Summary
Wuhan Hvsen competes with China State, Poly Real, China Vanke, China Merchants, and Huafa Industrial. Wuhan Hvsen is entity of China. It is traded as Stock on SHE exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | China Stock View All |
| Exchange | Shenzhen Stock Exchange |
| ISIN | CNE1000047H6 |
| Business Address | No208 Zhangbai Road, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.whhsyy.com |
| Phone | 86 27 8860 5516 |
You should never invest in Wuhan Hvsen without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Wuhan Stock, because this is throwing your money away. Analyzing the key information contained in Wuhan Hvsen's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Wuhan Hvsen Key Financial Ratios
Wuhan Hvsen's financial ratios allow both analysts and investors to convert raw data from Wuhan Hvsen's financial statements into concise, actionable information that can be used to evaluate the performance of Wuhan Hvsen over time and compare it to other companies across industries.| Revenue | 1.02 B | ||||
| Gross Profit | 222.75 M | ||||
| EBITDA | 150.08 M | ||||
| Net Income | 16.78 M | ||||
| Total Asset | 2.98 B |
Wuhan Hvsen Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Other Current Liab | 22.2M | 45.0M | 57.9M | 61.5M | 3.8M | 3.7M | |
| Other Liab | 24.3M | 28.0M | 45.0M | 72.4M | 83.3M | 87.4M | |
| Net Tangible Assets | 280.1M | 1.3B | 1.5B | 1.4B | 1.6B | 1.7B | |
| Retained Earnings | 191.6M | 341.8M | 429.3M | 427.1M | 341.9M | 271.4M | |
| Accounts Payable | 121.1M | 194.4M | 311.3M | 489.7M | 472.5M | 240.9M | |
| Other Assets | 26.0M | 67.0M | 25.9M | 32.7M | 37.6M | 26.7M | |
| Net Receivables | 107.0M | 201.7M | 259.5M | 338.0M | 318.5M | 190.8M | |
| Inventory | 72.4M | 127.3M | 231.6M | 199.0M | 228.7M | 144.0M | |
| Other Current Assets | 8.7M | 25.0M | 9.4M | 8.6M | 5.3M | 9.1M | |
| Total Current Assets | 292.5M | 1.2B | 1.6B | 1.4B | 1.3B | 863.0M | |
| Total Assets | 650.1M | 1.8B | 2.7B | 3.0B | 3.0B | 1.9B | |
| Cash | 104.5M | 345.3M | 1.1B | 424.0M | 293.6M | 375.3M | |
| Total Liab | 271.8M | 373.1M | 1.1B | 1.4B | 1.5B | 777.0M | |
| Net Invested Capital | 441.0M | 1.4B | 2.3B | 2.3B | 2.4B | 1.5B | |
| Net Working Capital | 88.8M | 838.5M | 1.1B | 546.5M | 484.9M | 510.8M | |
| Intangible Assets | 98.2M | 95.8M | 110.1M | 106.9M | 104.2M | 101.2M | |
| Short Long Term Debt | 29M | 63M | 100M | 220.1M | 240.3M | 124.2M |
Wuhan Hvsen Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 5.2M | 2.3M | 2.9M | 18.4M | 28.2M | 29.6M | |
| Income Tax Expense | 9.8M | 25.9M | 18.0M | 4.0M | 4.6M | 4.4M | |
| Tax Provision | 9.8M | 25.9M | 18.0M | 4.0M | (4.3M) | (4.1M) | |
| Net Interest Income | (4.5M) | 3.9M | 4.4M | (14.1M) | (24.3M) | (23.0M) | |
| Interest Income | 2.0M | 6.5M | 7.7M | 4.8M | 4.3M | 4.4M | |
| Total Revenue | 427.2M | 777.5M | 996.2M | 1.0B | 1.0B | 796.0M | |
| Gross Profit | 163.7M | 287.9M | 270.7M | 225.4M | 213.3M | 243.2M | |
| Operating Income | 82.2M | 178.0M | 136.2M | 79.3M | 41.9M | 82.1M | |
| Ebit | 72.9M | 162.4M | 135.3M | 61.0M | 70.2M | 111.9M | |
| Research Development | 21.1M | 28.4M | 46.9M | 40.1M | 44.6M | 34.5M | |
| Ebitda | 100.4M | 197.4M | 182.2M | 137.7M | 158.3M | 152.5M | |
| Cost Of Revenue | 263.5M | 489.6M | 725.5M | 797.5M | 806.5M | 552.8M | |
| Income Before Tax | 78.6M | 176.0M | 150.8M | 56.7M | 12.4M | 11.8M | |
| Net Income | 68.8M | 150.2M | 132.9M | 52.7M | 16.8M | 15.9M |
Wuhan Hvsen Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Wuhan Hvsen Biotechnology. It measures of how well Wuhan is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Wuhan Hvsen brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Wuhan had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Wuhan Hvsen has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Borrowings | 40.2M | (16.6M) | 61.7M | 81.6M | 93.8M | 98.5M | |
| Capital Expenditures | 123.1M | 230.8M | 600.1M | 428.9M | 184.3M | 227.9M | |
| End Period Cash Flow | 81.9M | 285.5M | 966.1M | 278.6M | 229.5M | 274.2M | |
| Change To Netincome | 5.0M | 8.3M | (5.1M) | 13.3M | 15.3M | 16.1M | |
| Change To Inventory | 8.8M | (55.8M) | (105.9M) | 30.4M | (28.1M) | (29.5M) | |
| Change In Cash | 4.2M | 203.6M | 680.6M | (687.5M) | (49.1M) | (46.6M) | |
| Free Cash Flow | (17.8M) | (182.5M) | (444.4M) | (332.2M) | (91.4M) | (96.0M) | |
| Depreciation | 12.1M | 19.1M | 28.5M | 61.9M | 120.4M | 126.4M | |
| Other Non Cash Items | 1.8M | 2.5M | 5.3M | 6.9M | 28.8M | 30.3M | |
| Dividends Paid | 16.7M | 6.0M | 47.9M | 62.5M | 58.6M | 37.4M | |
| Net Income | 68.8M | 150.2M | 132.9M | 52.7M | 16.8M | 15.9M |
Wuhan Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Wuhan Hvsen's current stock value. Our valuation model uses many indicators to compare Wuhan Hvsen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Wuhan Hvsen competition to find correlations between indicators driving Wuhan Hvsen's intrinsic value. More Info.Wuhan Hvsen Biotechnology is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Wuhan Hvsen by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Wuhan Hvsen's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Wuhan Hvsen Biotechnology Systematic Risk
Wuhan Hvsen's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Wuhan Hvsen volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Wuhan Hvsen Biotechnology correlated with the market. If Beta is less than 0 Wuhan Hvsen generally moves in the opposite direction as compared to the market. If Wuhan Hvsen Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Wuhan Hvsen Biotechnology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Wuhan Hvsen is generally in the same direction as the market. If Beta > 1 Wuhan Hvsen moves generally in the same direction as, but more than the movement of the benchmark.
Wuhan Hvsen Biotechnology Other Current Liab Over Time
Wuhan Hvsen Thematic Clasifications
Wuhan Hvsen Biotechnology is part of Biotech investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services
This theme covers Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services. Get More Thematic Ideas
| Biotech | View |
Wuhan Hvsen November 23, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Wuhan Hvsen help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Wuhan Hvsen Biotechnology. We use our internally-developed statistical techniques to arrive at the intrinsic value of Wuhan Hvsen Biotechnology based on widely used predictive technical indicators. In general, we focus on analyzing Wuhan Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Wuhan Hvsen's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.21 | |||
| Information Ratio | 0.0835 | |||
| Maximum Drawdown | 27.88 | |||
| Value At Risk | (3.85) | |||
| Potential Upside | 5.21 |
Complementary Tools for Wuhan Stock analysis
When running Wuhan Hvsen's price analysis, check to measure Wuhan Hvsen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Wuhan Hvsen is operating at the current time. Most of Wuhan Hvsen's value examination focuses on studying past and present price action to predict the probability of Wuhan Hvsen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Wuhan Hvsen's price. Additionally, you may evaluate how the addition of Wuhan Hvsen to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |